PuSH - Publikationsserver des Helmholtz Zentrums München

Zhang, S.* ; Schneider, L.S.* ; Vick, B. ; Grunert, M. ; Jeremias, I. ; Menche, D.* ; Müller, R.* ; Vollmar, A.M.* ; Liebl, J.*

Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.

Oncotarget 6, 43508-43528 (2015)
Verlagsversion Anhang DOI
Creative Commons Lizenzvertrag
Prognosis for patients suffering from T-ALL is still very poor and new strategies for T-ALL treatment are urgently needed. Our study shows potent anti-leukemic effects of the myxobacterial V-ATPase inhibitor Archazolid A. Archazolid A reduced growth and potently induced death of leukemic cell lines and human leukemic samples. By inhibiting lysosomal acidification, Archazolid A blocked activation of the Notch pathway, however, this was not the mechanism of V-ATPase inhibition relevant for cell death induction. In fact, V-ATPase inhibition by Archazolid A decreased the anti-apoptotic protein survivin. As underlying mode of action, this work is in line with recent studies from our group demonstrating that Archazolid A induced S-phase cell cycle arrest by interfering with the iron metabolism in leukemic cells. Our study provides evidence for V-ATPase inhibition as a potential new therapeutic option for T-ALL.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Archazolid ; Leukemia ; Natural Compounds; Acute Lymphoblastic-leukemia; Acute Myeloid-leukemia; Vacuolar H+-atpase; Chronic Lymphocytic-leukemia; Breast-cancer Cells; Therapeutic Target; Proton Pumps; Endoplasmic-reticulum; Drug-resistance; Notch Receptor
ISSN (print) / ISBN 1949-2553
e-ISSN 1949-2553
Zeitschrift OncoTarget
Quellenangaben Band: 6, Heft: 41, Seiten: 43508-43528 Artikelnummer: , Supplement: ,
Verlag Impact Journals LLC
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)